Sachetta LLC Buys 31 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sachetta LLC lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 33.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 125 shares of the medical equipment provider’s stock after buying an additional 31 shares during the period. Sachetta LLC’s holdings in Intuitive Surgical were worth $54,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Global X Japan Co. Ltd. increased its stake in Intuitive Surgical by 24.0% in the 2nd quarter. Global X Japan Co. Ltd. now owns 35,005 shares of the medical equipment provider’s stock worth $15,572,000 after purchasing an additional 6,766 shares during the period. LGT Group Foundation raised its holdings in Intuitive Surgical by 5.1% during the 2nd quarter. LGT Group Foundation now owns 55,026 shares of the medical equipment provider’s stock valued at $24,478,000 after buying an additional 2,650 shares during the last quarter. Liberty Wealth Management LLC purchased a new stake in Intuitive Surgical during the 2nd quarter valued at $4,969,000. Choreo LLC grew its holdings in Intuitive Surgical by 506.2% in the 2nd quarter. Choreo LLC now owns 13,149 shares of the medical equipment provider’s stock worth $5,740,000 after acquiring an additional 10,980 shares during the last quarter. Finally, Wedbush Securities Inc. increased its position in shares of Intuitive Surgical by 2.6% in the second quarter. Wedbush Securities Inc. now owns 14,905 shares of the medical equipment provider’s stock valued at $6,630,000 after acquiring an additional 371 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

ISRG has been the subject of a number of analyst reports. Morgan Stanley increased their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Truist Financial boosted their target price on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price target for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Piper Sandler boosted their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Finally, BTIG Research raised their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Up 1.0 %

ISRG stock opened at $484.24 on Wednesday. The business has a 50 day moving average of $460.51 and a 200 day moving average of $419.84. The firm has a market cap of $171.76 billion, a PE ratio of 87.41, a price-to-earnings-growth ratio of 5.20 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $493.97.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,655,048.26. The disclosure for this sale can be found here. Insiders sold 50,555 shares of company stock valued at $24,267,737 over the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.